Oculus Gets FDA Clearance For Novel Atopic Dermatitis Dermatology Product

(RTTNews) - Oculus Innovative Sciences, Inc. (OCLS) announced that it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's new Alevicyn SG Antipruritic Spray Gel with both prescription and over-the-counter indications.

Produced using the patented Microcyn Technology, The Alevicyn SG prescription product, under the supervision of a healthcare professional, is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis.

It may also be used to relieve the pain of first- and second-degree burns and helps to relieve dry waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.

In the United States, Alevicyn SG will launch in July 2015, via Oculus' direct dermatology sales force. Outside the United States, Oculus is working with its international distributors and partners to bring this novel technology to dermatology patients around the world.

In tandem with the prescription clearance, the Alevicyn SG Antipruritic Spray Gel has also been cleared for over-the-counter use in the United States. In this use, it is intended to relieve the burning and itching associated with many common types of skin irritation, lacerations, abrasions, and minor burns and is also indicated for the management of irritation and pain from minor burns, including sunburn.

OCLS closed Monday's regular trading at $1.76, up $0.41 or 30.37%. In after-hours, the share further gained $0.24 or 13.64%.